Key facts
- Notable investors include Oasis500.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Scigeniq
- ·The full record, as it builds
Funding rounds
No funding rounds for Scigeniq are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scigeniq
Developer of life sciences quality and regulatory compliance software designed to help mid-sized pharmaceutical and biotech companies digitize and streamline their quality, regulatory, and document management processes. The company's cloud-based quality management, regulatory submissions and document control applications embed pharma-specific best practices, support end-to-end workflows from deviation and CAPA through change control and submissions, and are tailored for life sciences organizations in regions such as the Middle East, Africa and South America, enabling these companies to accelerate digital transformation, ensure regulatory compliance and improve operational efficiency.
- Sector
- Healthcare
- HQ
- Dubai, United Arab Emirates
- Founded
- 2020
- Employees
- 15
- Website
- scigeniq.com/
- Ownership
- Privately Held (backing)
Scigeniq doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scigeniq shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scigeniq in its N-PORT filings yet. We sweep new filings monthly.